Normando Iznaga Selected Research

nimotuzumab

1/2018	Nimotuzumab: beyond the EGFR signaling cascade inhibition.
2/2011	Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile.
4/2010	Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study.
3/2010	Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck.
1/2009	Clinical experience with nimotuzumab in cuban pediatric patients with brain tumors, 2005 to 2007.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Normando Iznaga Research Topics

Disease

5	Neoplasms (Cancer) 01/2018 - 03/2003
2	Squamous Cell Carcinoma of Head and Neck 04/2010 - 03/2010
1	Head and Neck Neoplasms (Head and Neck Cancer) 04/2010
1	Exanthema (Rash) 04/2010
1	Brain Neoplasms (Brain Tumor) 01/2009

Drug/Important Bio-Agent (IBA)

5	nimotuzumabIBA 01/2018 - 01/2009
2	Monoclonal AntibodiesIBA 04/2010 - 03/2003
2	ErbB Receptors (EGF Receptor)IBA 04/2010 - 03/2003
1	Immunoglobulin Fab FragmentsIBA 02/2011
1	Cetuximab (Erbitux)FDA Link 02/2011
1	AntibodiesIBA 02/2011
1	Biomarkers (Surrogate Marker)IBA 03/2010

Therapy/Procedure

2	Chemoradiotherapy 04/2010 - 03/2010
1	Immunotherapy 01/2018
1	Therapeutics 04/2010
1	Radiotherapy 03/2010
1	Time-to-Treatment 03/2010
1	Intravenous Infusions 03/2003